Esomeprazole Magnesium Hydrate
Tier C — Watch / tradeEsomeprazole Magnesium Hydrate
Targets:Proton pump
Brand:Nexium, Nexium 24HR
Indications (approved):Heartburn, Gastro-oesophageal reflux disease, Duodenal ulcer, Gastric ulcer, Peptic oesophagitis, Helicobacter pylori infection, Zollinger-Ellison syndrome, Oesophagitis
Regional status
Factories producing this API2
Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.
2 producing factories on file — sign in to view the named list (factory details are not shown to guests).
Sign in to view factories →Synthetic routes & intermediates5 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| ESOME-001 | 86604-78-6 | (4-methoxy-3,5-dimethylpyridin-2-yl)methanol |
| ESOME-002 | 84006-10-0 | 2-(chloromethyl)-4-methoxy-3,5-dimethylpyridine |
| ESOME-003 | 37052-78-1 | 5-methoxy-1H-benzo[d]imidazole-2-thiol |
| ESOME-004 | 73590-85-9 | 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)thio)-1H-benzo[d]imidazole |
| ESOME-005 | 73590-58-6 | 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
| ESOME-006 | 119141-88-7 | (S)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
| ESOME-007 | 161796-78-7 | sodium (S)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide |
| Code | CAS No. | Intermediate |
|---|---|---|
| ESOME-005 | 73590-58-6 | 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
| ESOME-006 | 119141-88-7 | (S)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
| ESOME-008 | 95510-70-6 | sodium 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide |
| ESOME-009 | 13811-71-7 | diethyl (2S,3S)-2,3-dihydroxysuccinate |
| ESOME-010 | - | sodium (R)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)(methyl)(oxo)-l5-sulfanyl)benzo[d]imidazol-1-ide |
| ESOME-011 | 1429047-64-2 | - |
| Code | CAS No. | Intermediate |
|---|---|---|
| ESOME-005 | 73590-58-6 | 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
| ESOME-006 | 119141-88-7 | (S)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
| ESOME-012 | 118293-34-8 | (6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-1-yl)methanol |
| ESOME-013 | 118293-26-8 | 1-(chloromethyl)-6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
| ESOME-014 | 611-71-2 | (R)-2-hydroxy-2-phenylacetic acid |
| ESOME-015 | - | (6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-1-yl)methyl (2R)-2-hydroxy-2-phenylacetate |
| ESOME-016 | 161796-87-8 | (6-methoxy-2-((S)-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazol-1-yl)methyl (R)-2-hydroxy-2-phenylacetate |
| Code | CAS No. | Intermediate |
|---|---|---|
| ESOME-005 | 73590-58-6 | 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole |
| ESOME-007 | 161796-78-7 | sodium (S)-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide |
| ESOME-017 | 18531-99-2 | [1,1'-binaphthalene]-2,2'-diol |
| ESOME-018 | - | [1,1'-binaphthalene]-2,2'-diol compound with 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole (1:1) |
| ESOME-019 | 108-21-4 | isopropyl acetate |
| Code | CAS No. | Intermediate |
|---|---|---|
| ESOME-004 | 73590-85-9 | 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)thio)-1H-benzo[d]imidazole |
| ESOME-009 | 13811-71-7 | diethyl (2S,3S)-2,3-dihydroxysuccinate |
Frequently asked questions
What are the approved indications of Esomeprazole Magnesium Hydrate?
Approved indications include: Heartburn, Gastro-oesophageal reflux disease, Duodenal ulcer, Gastric ulcer, Peptic oesophagitis, Helicobacter pylori infection, Zollinger-Ellison syndrome, Oesophagitis.
When does the Esomeprazole Magnesium Hydrate patent expire?
No public expiry year is available for Esomeprazole Magnesium Hydrate yet; this page updates once verified.
How many synthesis routes are recorded for Esomeprazole Magnesium Hydrate?
5 synthesis routes are recorded; the shortest is 1 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Esomeprazole Magnesium Hydrate intermediates?
All intermediates in Esomeprazole Magnesium Hydrate routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Esomeprazole Magnesium Hydrate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27